Development of a kinetic antibody-dependent cellular cytotoxicity assay

Area of Science:

• Immunology
• Pharmacology
• Biotechnology

Background:

• Antibody-dependent cellular cytotoxicity (ADCC) is a critical mechanism of action for monoclonal antibody (mAb) therapies.
• Characterizing ADCC activity is essential for evaluating mAb efficacy and safety during drug development.
• Current in vitro ADCC assays often rely on endpoint measurements, limiting real-time analysis of cell lysis.

Purpose of the Study:

• To develop and characterize a novel kinetic assay for measuring ADCC.
• To evaluate the performance of the kinetic ADCC assay across various target and effector cell types.
• To establish the kinetic ADCC assay as a viable alternative to existing in vitro methods.

Main Methods:

• Development of a kinetic assay to directly measure ADCC-mediated cell lysis over time.
• Characterization of the assay's performance using multiple target and effector cell combinations.
• Comparison of the kinetic assay's sensitivity and efficiency against a standard endpoint fluorescence release ADCC assay.

Main Results:

• The developed kinetic ADCC assay is applicable to diverse target and effector cell types.
• The kinetic assay demonstrated comparable sensitivity to the endpoint fluorescence release ADCC assay.
• The kinetic assay offers advantages including simpler setup and reduced assay time.

Conclusions:

• Kinetic ADCC assay provides a robust and efficient method for in vitro assessment of mAb activity.
• This assay format is a valid alternative for characterizing ADCC in monoclonal antibody drug development.
• The kinetic approach enhances the evaluation of mAb efficacy and safety through real-time lysis measurement.